A study to assess Feasibility, efficacy, and safety of using dolutegravir/lamivu- dine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed Patients living with HIV
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Dolutegravir/lamivudine (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms STAT
- 26 Oct 2022 Results assessing patient reported symptom burden through week 48, presented at the 16th International Congress on Drug Therapy and HIV Infection.
- 21 Jul 2021 Results of 48-week end-of-study results presented at the 11th International AIDS Society Conference on HIV Science
- 17 Jul 2021 According to ViiV Healthcare media release, results will be presented at the International AIDS Society Conference 2021 (IAS 2021)